In contrast, mutations in PIK3CD and CREBBP were associated with inferior outcomes in T-cell lymphomas, highlighting the immunophenotype-specific impact of genetic alterations on treatment responses. Here, CREBBP is linked to T-cell non-Hodgkin lymphoma.